S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
Log in
OTCMKTS:ASPCF

Acerus Pharmaceuticals Stock Forecast, Price & News

$0.03
0.00 (0.00 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.05
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.02
Now: $0.03
$0.09
Volume14,000 shs
Average Volume27,280 shs
Market Capitalization$46.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform that offer applications for pulmonary and nasal pharmaceutical medications. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

MarketRank

Overall MarketRank

0.44 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ASPCF
CUSIPN/A
CIKN/A
Phone416-679-0771
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.77 million
Book Value($0.05) per share

Profitability

Net Income$-16,130,000.00
Net Margins-1,596.69%

Miscellaneous

Outstanding Shares1,537,588,000
Market Cap$46.13 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable
$0.03
0.00 (0.00 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASPCF News and Ratings via Email

Sign-up to receive the latest news and ratings for ASPCF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acerus Pharmaceuticals (OTCMKTS:ASPCF) Frequently Asked Questions

How has Acerus Pharmaceuticals' stock price been impacted by Coronavirus?

Acerus Pharmaceuticals' stock was trading at $0.0380 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASPCF stock has decreased by 21.1% and is now trading at $0.03.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Acerus Pharmaceuticals?

Wall Street analysts have given Acerus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acerus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Acerus Pharmaceuticals
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) issued its earnings results on Monday, November, 2nd. The company reported ($0.01) EPS for the quarter. The business had revenue of $0.49 million for the quarter. Acerus Pharmaceuticals had a negative net margin of 1,596.69% and a negative return on equity of 1,335.69%.
View Acerus Pharmaceuticals' earnings history
.

Are investors shorting Acerus Pharmaceuticals?

Acerus Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totaling 13,700 shares, a decline of 58.1% from the December 15th total of 32,700 shares. Based on an average daily trading volume, of 13,900 shares, the days-to-cover ratio is presently 1.0 days.
View Acerus Pharmaceuticals' Short Interest
.

Who are some of Acerus Pharmaceuticals' key competitors?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Mr. Edward Gudaitis, Pres, CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Gavin Damstra, Sr. VP of International Commercial
  • Mr. Chris Witty, Investor Relations
  • Dr. Christopher Sorli Ph.D., M.D., F.A.C.E., Chief Medical Officer
  • Mr. Kevin Thomas Hickey, Sr. VP of US Commercial
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $0.03.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of $46.13 million and generates $3.77 million in revenue each year. Acerus Pharmaceuticals employs 11 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The company can be reached via phone at 416-679-0771 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.